<?xml version="1.0" encoding="UTF-8"?>
<ref id="B18">
 <label>18.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Vannice</surname>
    <given-names>KS</given-names>
   </name>
   <name>
    <surname>Wilder-Smith</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Barrett</surname>
    <given-names>ADT</given-names>
   </name>
   <name>
    <surname>Carrijo</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Cavaleri</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>de</surname>
    <given-names>SA</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines</article-title>. 
  <source>Vaccine</source>. (
  <year>2018</year>) 
  <volume>36</volume>:
  <fpage>3411</fpage>â€“
  <lpage>7</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.062</pub-id>
  <?supplied-pmid 29525283?>
  <pub-id pub-id-type="pmid">29525283</pub-id>
 </mixed-citation>
</ref>
